Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors
NCT04681248 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2025-08-03
Summary
An Expanded Access Protocol for use of DKN-01 for the treatment of advanced solid tumors.
Conditions
- Esophageal Neoplasm
- Adenocarcinoma of the Gastroesophageal Junction
- GastroEsophageal Cancer
- Squamous Cell Carcinoma
- Gastric Adenocarcinoma
- Endometrial Cancer
- Uterine Cancer
- Ovarian Cancer
- Carcinosarcoma
- Gastric Cancer
Interventions
- DRUG
-
DKN-01
Administered by IV infusion
Sponsors & Collaborators
-
Leap Therapeutics, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer
NCT01248962 ·Status: COMPLETED ·Phase: PHASE2
-
Dactinomycin in Treating Patients With Persistent or Recurrent Gestational Trophoblastic Neoplasia
NCT00003688 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer
NCT00058552 ·Status: COMPLETED ·Phase: PHASE2
-
BKM120 in Advanced, Metastatic, or Recurrent Endometrial Cancers
NCT01550380 ·Status: WITHDRAWN ·Phase: PHASE2
-
Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02659241 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma
NCT00758732 ·Status: TERMINATED ·Phase: PHASE2
-
Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients
NCT02028117 ·Status: COMPLETED ·Phase: PHASE1
-
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
NCT00282087 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer
NCT00806156 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
NCT05588648 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00939809 ·Status: COMPLETED ·Phase: PHASE2
-
Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer
NCT00214058 ·Status: COMPLETED ·Phase: PHASE2
-
Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
NCT00379145 ·Status: COMPLETED ·Phase: PHASE2
-
Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer
NCT00357448 ·Status: COMPLETED ·Phase: PHASE1
-
Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer
NCT00010179 ·Status: COMPLETED ·Phase: PHASE2
-
UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00072267 ·Status: COMPLETED ·Phase: PHASE2
-
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
NCT04585958 ·Status: RECRUITING ·Phase: PHASE1
-
Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer
NCT00466986 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer
NCT06686030 ·Status: RECRUITING ·Phase: PHASE2
-
Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer
NCT00102414 ·Status: COMPLETED ·Phase: PHASE3
-
Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer
NCT01322802 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer
NCT03029585 ·Status: TERMINATED ·Phase: PHASE2
-
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma
NCT03668340 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
NCT02090127 ·Status: NO_LONGER_AVAILABLE
-
UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
NCT00045175 ·Status: COMPLETED ·Phase: PHASE1